Nivolumab Antibody ELISA 试剂盒
适用: 人, 猴, 小鼠, 大鼠
Colorimetric
Sandwich ELISA
Plasma, Serum
1 image
-
- 抗原
- Nivolumab Antibody
- 适用
- 人, 猴, 小鼠, 大鼠
- 检测方法
- Colorimetric
- 实验类型
- Sandwich ELISA
- 应用范围
- ELISA
- 原理
- Enzyme immunoassay for the semi-quantitative determination of free antibodies to Nivolumab (Opdivo®) in serum and plasma.
- 样品类型
- Plasma, Serum
- Analytical Method
- Semi-Quantitative
- 组件
- plate, standards, assay buffer, conjugate, TMB, HCl, wash buffer
- 试剂未包括
- normal lab equipment for performing ELISA assays
-
- 样本量
- 20 μL
- 实验时间
- 1.5 h
- 板类型
- Pre-coated
- 实验流程
- This anti-drug antibody(ies) (ADA) kit is a bridging type ELISA for the determination of free antibodies against the drug Nivolumab in serum and plasma samples. During the first incubation period, ADA in serum or plasma samples are captured by the drug coated on the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled drug conjugate is added and then incubated. ADA, if present in sample, will make a bridge, with its identical Fab arms, between the drug coated on the well and the other drug molecule labelled with peroxidase. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with stop solution. The positive reaction is expected to be related to the presence of ADA in the sample.
- 试剂准备
-
Just the wash buffer has to be prepared by diluting the stock solution 1:20. All other reagents are ready to use.
- 样品收集
- normal serum or plasma collection
- 样品制备
-
dilute the samples 1:20 with assay buffer
- 结果分析
-
The results are read from a standard curve.
- 实验精密度
- < 10%
- 限制
- 仅限研究用
-
- 储存液
- Sodium azide
- 储存条件
- 4 °C
- 有效期
- 24 months
-
- 抗原
- Nivolumab Antibody
- 物质类
- Antibody
- 背景
- The drug Nivolumab (Opdivo®) is a fully human IgG4 monoclonal antibody that binds specifically to programmed death-1 (PD-1), a negative regulatory receptor expressed by activated T and B lymphocytes. Binding of Nivolumab to the PD-1 receptor blocks its interaction with the ligands, PDL1 and PD-L2, thereby attenuating PD-1-mediated inhibition of the immune response, including the anti-tumor immune response. One of the major concerns, despite of its wide usage, is the potential development of anti-drug antibodies (ADA) which in turn may interfere with the drug efficacy as mainly judged by observing the relapse of signs and symptoms of disease and necessitate dose-escalation or potentially ending up the treatment. The "Antibody to Nivolumab" ELISA Kit can be used for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug.
-
You are here:
